SI3484467T1 - Kombinacija čistih 5-HT receptor antagonistov z inhibitorji acetilholinesteraze - Google Patents
Kombinacija čistih 5-HT receptor antagonistov z inhibitorji acetilholinesterazeInfo
- Publication number
- SI3484467T1 SI3484467T1 SI201630791T SI201630791T SI3484467T1 SI 3484467 T1 SI3484467 T1 SI 3484467T1 SI 201630791 T SI201630791 T SI 201630791T SI 201630791 T SI201630791 T SI 201630791T SI 3484467 T1 SI3484467 T1 SI 3484467T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pure
- combination
- receptor antagonists
- acetylcholinesterase inhibitors
- acetylcholinesterase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/305—Mercury compounds
- A61K31/31—Mercury compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641017205 | 2016-05-18 | ||
| PCT/IB2016/054673 WO2017199071A1 (en) | 2016-05-18 | 2016-08-03 | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors |
| EP16766622.1A EP3484467B1 (en) | 2016-05-18 | 2016-08-03 | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3484467T1 true SI3484467T1 (sl) | 2020-10-30 |
Family
ID=56940098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201630791T SI3484467T1 (sl) | 2016-05-18 | 2016-08-03 | Kombinacija čistih 5-HT receptor antagonistov z inhibitorji acetilholinesteraze |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US11458135B2 (sl) |
| EP (1) | EP3484467B1 (sl) |
| JP (1) | JP6606299B2 (sl) |
| KR (1) | KR102015484B1 (sl) |
| CN (2) | CN114642667A (sl) |
| AU (1) | AU2016407427B2 (sl) |
| BR (1) | BR112018073419A2 (sl) |
| CA (1) | CA3023819C (sl) |
| CY (1) | CY1123013T1 (sl) |
| DK (1) | DK3484467T3 (sl) |
| EA (1) | EA036347B1 (sl) |
| ES (1) | ES2796181T3 (sl) |
| HR (1) | HRP20200872T1 (sl) |
| HU (1) | HUE050819T2 (sl) |
| IL (1) | IL262921B (sl) |
| LT (1) | LT3484467T (sl) |
| MA (1) | MA45639B1 (sl) |
| MD (1) | MD3484467T2 (sl) |
| ME (1) | ME03731B (sl) |
| MX (1) | MX381768B (sl) |
| NZ (1) | NZ748280A (sl) |
| PL (1) | PL3484467T3 (sl) |
| PT (1) | PT3484467T (sl) |
| RS (1) | RS60422B1 (sl) |
| SG (1) | SG11201809856SA (sl) |
| SI (1) | SI3484467T1 (sl) |
| SM (1) | SMT202000292T1 (sl) |
| WO (1) | WO2017199071A1 (sl) |
| ZA (1) | ZA201807468B (sl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111084776A (zh) * | 2018-10-24 | 2020-05-01 | 中国科学院昆明动物研究所 | 匹立尼酸及其衍生物用于治疗和/或预防神经退行性疾病的用途 |
| CN111084768A (zh) * | 2018-10-24 | 2020-05-01 | 中国科学院昆明动物研究所 | 吉非罗齐及其衍生物用于治疗和/或预防神经退行性疾病的用途 |
| BR112022010493A2 (pt) * | 2019-12-02 | 2022-09-06 | Suven Life Sciences Ltd | Métodos para tratar sintomas comportamentais e psicológicos em pacientes com demência |
| MX2022006537A (es) * | 2019-12-02 | 2022-12-13 | Suven Life Sciences Ltd | Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003237599B2 (en) | 2002-11-28 | 2009-06-18 | Suven Life Sciences Limited | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them |
| CA2507923C (en) * | 2002-12-18 | 2010-02-02 | Suven Life Sciences Limited | Tetracyclic 3-substituted indoles having serotonin receptor affinity |
| PE20071143A1 (es) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
| PT2040755E (pt) | 2006-06-23 | 2011-07-08 | Esteve Labor Dr | Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6 |
| AR061637A1 (es) | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
| JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
| IN2013CH05537A (sl) | 2013-12-02 | 2015-06-12 | Suven Life Sciences Ltd | |
| KR101938408B1 (ko) * | 2014-08-16 | 2019-01-14 | 수벤 라이프 사이언시스 리미티드 | 1-[(2-브로모페닐) 술포닐]-5-메톡시-3-[(4-메틸-1-피페라지닐) 메틸]-1h-인돌 디메실레이트 모노히드레이트의 활성 대사산물 및 상기 활성 대사산물의 디메실레이트 디히드레이트 염 |
-
2016
- 2016-08-03 MX MX2018014185A patent/MX381768B/es unknown
- 2016-08-03 AU AU2016407427A patent/AU2016407427B2/en active Active
- 2016-08-03 SG SG11201809856SA patent/SG11201809856SA/en unknown
- 2016-08-03 ME MEP-2020-109A patent/ME03731B/me unknown
- 2016-08-03 LT LTEP16766622.1T patent/LT3484467T/lt unknown
- 2016-08-03 CN CN202210321209.2A patent/CN114642667A/zh active Pending
- 2016-08-03 PL PL16766622T patent/PL3484467T3/pl unknown
- 2016-08-03 KR KR1020187035983A patent/KR102015484B1/ko active Active
- 2016-08-03 RS RS20200635A patent/RS60422B1/sr unknown
- 2016-08-03 CN CN201680085574.0A patent/CN109069468A/zh active Pending
- 2016-08-03 PT PT167666221T patent/PT3484467T/pt unknown
- 2016-08-03 SI SI201630791T patent/SI3484467T1/sl unknown
- 2016-08-03 EA EA201892529A patent/EA036347B1/ru unknown
- 2016-08-03 MA MA45639A patent/MA45639B1/fr unknown
- 2016-08-03 MD MDE20190594T patent/MD3484467T2/ro unknown
- 2016-08-03 HU HUE16766622A patent/HUE050819T2/hu unknown
- 2016-08-03 NZ NZ748280A patent/NZ748280A/en unknown
- 2016-08-03 SM SM20200292T patent/SMT202000292T1/it unknown
- 2016-08-03 WO PCT/IB2016/054673 patent/WO2017199071A1/en not_active Ceased
- 2016-08-03 DK DK16766622.1T patent/DK3484467T3/da active
- 2016-08-03 JP JP2018559336A patent/JP6606299B2/ja active Active
- 2016-08-03 ES ES16766622T patent/ES2796181T3/es active Active
- 2016-08-03 BR BR112018073419-5A patent/BR112018073419A2/pt not_active Application Discontinuation
- 2016-08-03 EP EP16766622.1A patent/EP3484467B1/en active Active
- 2016-08-03 US US16/099,161 patent/US11458135B2/en active Active
- 2016-08-03 CA CA3023819A patent/CA3023819C/en active Active
- 2016-08-03 HR HRP20200872TT patent/HRP20200872T1/hr unknown
-
2018
- 2018-11-07 ZA ZA2018/07468A patent/ZA201807468B/en unknown
- 2018-11-11 IL IL262921A patent/IL262921B/en active IP Right Grant
-
2020
- 2020-05-29 CY CY20201100489T patent/CY1123013T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3125893T3 (pl) | Deuterowane gamma-karboliny w fuzji z heterocyklami jako antagoniści receptorów 5-HT2A | |
| IL276400A (en) | Dopamine D3 receptor antagonist compounds | |
| IL284005A (en) | Glucocorticoid receptor inhibitors | |
| IL254476A0 (en) | Heterocyclylmethyl-thianouracil as adenosine-a2b receptor antagonists | |
| GB201519195D0 (en) | CGRP Receptor Antagonists | |
| IL262921B (en) | Combination of pure 5-HT6 receptor antagonists with acetylcholinesterase inhibitors | |
| EP3350167A4 (en) | Androgen receptor Antagonist | |
| GB201519194D0 (en) | CGRP receptor antagonists | |
| ZA201807311B (en) | Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist | |
| IL262920B (en) | Triple combination of pure 5-HT6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor agonist | |
| EP3277665A4 (en) | Indole analogs as 5-oxo-ete receptor antagonists and method of use thereof | |
| ZA202000758B (en) | Fluoropiperidine compounds as pure 5-ht6 receptor antagonists | |
| IL264406B (en) | Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors |